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Comparison of CD23 staining patterns
in Merkel cell carcinoma and
non-cutaneous small cell carcinoma
Background: During our daily practice, we observed that cluster
designation 23 (CD23) (clone BU38) labels Merkel cells in normal skin.
In this study, we examined the expression of CD23 in Merkel cell
carcinoma (MCC) and assessed its usefulness in distinguishing MCC
from non-cutaneous small cell carcinoma (SMCC).
Methods: Immunohistochemical staining of CD23 was performed
on a total of 33 MCCs, 22 SMCCs and 5 carcinoid tumors.
Results: CD23 reactivity was present in 32 of 33 (97%) MCCs, 18 of
22 (82%) SMCCs and 5 of 5 (100%) carcinoid tumors. In MCC, 19
cases (59%) showed a predominance of perinuclear dot-like staining
similar to cytokeratin 20, 3 (9%) showed mostly cytoplasmic staining
and 10 (31%) displayed a combination of perinuclear dot-like and
cytoplasmic staining. In contrast, all CD23-positive SMCCs and
carcinoid tumors showed a diffuse cytoplasmic staining. There was
a significant difference in the CD23 staining patterns between MCC
and SMCC (p , 0.0001).
Conclusion: CD23 is expressed in the majority of MCC, SMCC
and carcinoid tumor irrespective of clinical outcome. The distinct
punctate CD23 staining for MCC may be helpful in differentiating it
from SMCC. To our knowledge, this is the first study to show the
expression of CD23 in neuroendocrine tumors.
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Cluster designation 23 (CD23) is the low-affinity
receptor for IgEand iswell documented as a lymphoid
marker.1,2 Apart from its primary use in diagnosing
chronic lymphocytic leukemia/small cell lym-
phoma,3 CD23 expression has recently been detected
in the glandular epithelium of breast, colon and the
eccrine/apocrine secretory coils of sweat glands, as
well as in several cutaneous sweat gland tumors.4,5
Merkel cell carcinoma (MCC) is a rare primary
undifferentiated small cell carcinoma (SMCC) of the
skin that arises mostly in sun-exposed skin of elderly
individuals.6 It is an aggressive cutaneous carcinoma
with high rates of recurrence and metastasis.7 In
clinical practice, MCC and cutaneous metastatic
SMCC of the lung share common histologic features
and therefore frequently present a diagnostic chal-
lenge. The distinction between MCC and lung
SMCC has significant prognostic and therapeutic
implications.
Previous studies have shown that cytokeratin 20
(CK20) is positive in the majority of MCC, although
lung SMCC may occasionally show CK20 reactiv-
ity.8,9 CK20 has also been shown to be helpful in
detecting occult metastases ofMCC in sentinel lymph
nodes.10 Thyroid transcription factor-1 (TTF-1) is
frequently expressed in lung SMCC11 but not in
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MCC.12 When used in combination with TTF-1,
CK20 is helpful in differentiating MCC from lung
SMCC.13 Recently, some new immunohistochemical
markers, such as CD117 andCD56, have been shown
to be expressed by neuroendocrine carcinomas, but
few of them seem to be specific for MCC.14–19
During our study of CD23 expression in cutaneous
adnexal tumors, we discovered that CD23 labeled
Merkel cells in normal skin. To expand this finding,
we investigated the potential utilization of CD23
in diagnosing MCC and perhaps in differentiating
MCC from non-cutaneous SMCC. We report herein
thatCD23 is constantly expressed inMCC (97%)with
characteristic punctate staining, a well-recognized
reaction pattern for CK20. Although a substantial
number of non-cutaneous SMCCs (82%) are also




After approval from the University of Michigan
Institutional Review Board for human subject
research, a search of the laboratory files of the
University of Michigan, Pathology Department from
January 1996 to May 2006 was performed. We
identified 33 cases of MCC in 28 patients of which 25
were primary skin lesions and 8 were lymph node
metastases. Among these, we had the corresponding
sentinel lymph node specimens available for five skin
lesions from five individual patients. As comparison,
22 cases of non-cutaneous SMCC, including 16
pulmonary (10 primary, 6 metastases to skin, liver,
adrenal, mediastinum or soft tissue) and 6 extrap-
ulmonary tumors (2 urinary bladder, 1 ethmoid, 1
tonsil, 1 esophagus and 1 vocal cord), were examined.
In addition, five cases of carcinoid tumor (four
bronchus/lung and one duodenum) were evaluated.
Hematoxylin and eosin sections and all prior
immunohistochemical stains (i.e. pancytokeratins,
CK20, TTF-1, CD56, chromogranin A or synapto-
physin) were reviewed to confirm the original
diagnoses.20,21 All MCCs included in this study were
positive for CK20 and/or pancytokeratin and
negative for TTF-1.
Immunohistochemical detection of CD23
Immunohistochemical study was performed on
formalin-fixed and paraffin-embedded tissue sections
on a Ventana Benchmark XT system (Ventana
Medical Systems,Tucson,AZ,USA) using the iVIEW
diaminobenzidine reaction kit for visualization. All
slides were pretreated with protease for 16 min before
applying the mouse anti-human monoclonal CD23
antibody (clone BU38; 1 : 10 dilution; The Binding
Site, San Diego, CA, USA).
The immunoreactivity of the tumor cells was
independently evaluated by two pathologists (L. M.
and J. C.) according to the pattern, distribution and
intensity of the CD23 staining. Cases were considered
positive if more than 1% of tumor cells were immu-
noreactive. The staining pattern was stratified into
three groups: diffuse cytoplasmic labeling, perinuclear
dot-like staining or both. The percentage of positive
tumor cells was recorded as one of three categories:
. 50%, 20–50% and , 20%. The intensity of
staining was graded as weak or moderate to strong.
Statistical analysis
Statistical analysis was carried out using SAS 8.2
software (SAS Institute Inc., Cary, NC, USA). The
Fisher’s exact test was used to assess the difference in
CD23 staining patterns betweenMCCandSMCC.A
p value, 0.05was considered statistically significant.
Results
In normal skin, CD23 expression was detected in the
secretory epithelium of sweat glands (data not shown),
as well as rare isolatedMerkel cells in the basal layer of
the epidermis and the outer root sheath of hair follicles
(Fig. 1A). In the lung, it was observed in bronchial
epithelium and some pneumocytes (data not shown).
We studied CD23 expression in 33MCCs, 22 non-
cutaneous SMCCs and 5 carcinoid tumors that were
fully characterized histologically and immunopheno-
typically. The results are summarized in Table 1.
The MCC patients included in our study were 22
men and 11women, with an age range of 44–87 years
old (mean ¼ 73 years). With the exception of one
primary skin tumor, 32 MCCs consistently expressed
CD23, with four cases showing weak staining and 28
having moderate-to-strong staining, resulting in an
overall sensitivity of 97%. Among cases that had
CD23 expression, 19 of 32 (59%) showed a pre-
dominance of perinuclear dot-like pattern (Fig. 1C)
that closely resembled CK20 reactivity in MCC
(Fig. 1B). Ten of 32 (31%) cases displayed a combina-
tion of dot-like and diffuse cytoplasmic (some with
membrane accentuation) staining, while the remain-
ing three cases (9%) showed a mainly diffuse
cytoplasmic/membranous pattern. In 20 of the 32
positive cases (14/24 primary skin tumors and 6/8
nodal metastases), CD23 was detected in greater than
50% of the tumor cells. No differences in staining
patterns were observed between 24 primary skin
MCCs and 8 lymph node metastases. Similar to
primary skin lesions, six of eight nodal metastases
showed a characteristic punctate CD23-positivity,
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while two showed a combined cytoplasmic and
punctate staining (Fig. 1D). Among 25 cases of
primary MCC, 16 had a sentinel lymph node biopsy
performed. Twelve of 16 patients had positive sentinel
lymph node(s) for metastatic MCC, while four
patients showed no evidence of nodal disease. When
the primary lesions from these two groups of patients
were compared, no appreciable difference in CD23
staining was noted, indicating that CD23 expression
does not correlate with MCC progression or metas-
tasis. We also compared the primary skin tumor with
its corresponding lymph node metastasis in five
different patients and found no difference in the
intensity and pattern of CD23 expression. Again, the
intensity, distribution and pattern of CD23 expression
did not appear to correlate with clinical outcomes in
this small cohort of patients.
In the non-cutaneous SMCC group (10 primary
lung tumor, 6 metastases of lung tumor and 6 extra-
pulmonary tumor), there were 15 men and 7 women,
with an age range of 42–83 years (mean ¼ 60 years).
Typically, the pulmonary and extrapulmonary tumors
exhibited identical morphologic features and were
composed of sheets of small round/ovoid cells with
hyperchromatic nuclei and scant cytoplasm (Fig. 2A).
As shown in Table 1, CD23 expression was detected
in 18 of 22 (82%) SMCCs (2 weak and 16 moderate
to strong) with a sensitivity of 82%. The positive
cases included 15 of 16 (94%) lung SMCCs and 3 of
6 (50%) extrapulmonary SMCCs from various sites.
Themajority (12/18, 67%) of CD23-positive SMCCs
had. 50% tumor cells stained. In contrast to MCC,
all positive cases displayed a diffuse cytoplasmic/
membranous staining (Fig. 2B). Interestingly, the only
case of skinmetastasis of lung SMCC showed a diffuse
cytoplasmic staining rather than a punctate pattern
(Fig. 2C). Statistically, the CD23 reaction patterns
were significantly different between MCC and non-
cutaneous SMCC groups (p , 0.0001).
We next studied five carcinoid tumors. CD23
reactivity was detected in all five lesions (twoweak and
three moderate to strong), with four showing. 50%
tumor cells stained (Fig. 2D). All five tumors showed
diffuse cytoplasmic staining, although one had very
focal punctate labeling. Interestingly, two cases with
weakCD23 reactivitywere both spindle cell bronchial
carcinoid tumors. Our findings indicate that CD23
expression is not restricted to neuroendocrine carci-
nomas. Instead, it may be a useful marker for
neuroendocrine tumors in general.
Discussion
To our knowledge, this was the first study to
investigate the CD23 expression in Merkel cells,










Perinuclear dot 19 0 0
Cytoplasmic 3 18 4
Cytoplasmic and perinuclear dot 10 0 1
Percentage of tumor cells staining
Negative (, 1%) 1 4 0
, 20% 4 3 0
20–50% 8 3 1
. 50% 20 12 4
CD23, cluster designation 23; MCC, Merkel cell carcinoma; SMCC, small
cell carcinoma.
Fig. 1. The expression of cluster designation
23 (CD23) in normal skin and Merkel cell
carcinomas (MCCs). A) CD23 labels several
small cells with scant cytoplasm exclusively
located in the basal layer of skin, features
typical of Merkel cells (3400). B) Punctate
pattern of cytokeratin 20 staining in a pri-
mary MCC (3400). C) Characteristic peri-
nuclear dot-like CD23 staining in a primary
MCC (3400). D) Perinuclear dot-like CD23
labeling (indicated by asterisk and inset on
lower right corner) in a lymph node metas-
tasis of MCC (3200). Adjacent normal
germinal center B cells (indicated by arrow
and inset on lower left corner) are also
marked by CD23 and can be easily distin-
guished from the tumor cells.
Carvalho et al.
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MCC, non-cutaneous SMCC and carcinoid tumor.
We report that the expression of CD23 is not limited
to lymphoid cells, but is also detected in Merkel cells
in normal skin as well as in some neuroendocrine
tumors.
CK20 is a well-accepted marker for primary
cutaneous MCC with a reported sensitivity of 95%.9
However, it is not entirely specific forMCCbecause it
can be identified in roughly 30% of lung SMCCs in
less than 25% of tumor cells.13 Occasional MCCs
have been found to be CK20 negative,9 and in such
cases, an expanded battery of neuroendocrine
markers, including synaptophysin, chromogranin A,
neuron-specific enolase and CD56, may help sub-
stantiate the diagnosis.22 In this study, the detection of
strong CD23 expression in MCC and non-cutaneous
SMCC is intriguing. Because CD23 displayed a
similar sensitivity (97%) as that described for CK20
(95%), it could serve as a useful adjunct marker to
CK20 for occasional CK20-negative MCC.9
In practice, MCC and non-cutaneous SMCC are
diagnosed by their characteristic histologic features
and the expression of typical neuroendocrine mar-
kers. The expression of CK20 inMCC and TTF-1 in
lungSMCCaids in the distinction between the two. In
our series, the CD23 expression in MCC is particu-
larly notable for its perinuclear dot-like reactivity, a
finding similar to that described for CK20.23
Although our results indicate thatCD23 is not specific
for MCC, the distinct punctate CD23 staining for
MCC makes it a potential adjunct immunohisto-
chemical marker in distinguishing betweenMCCand
non-cutaneous SMCC.
Recently,Ki-67was shown to be a prognostic factor
in MCC.24 In this study, we did not find a significant
correlation between the intensity and pattern of
CD23 reactivity and the metastatic potential of
primary MCC. The fact that five nodal metastases
of MCC displayed similar CD23 staining to their
cognate primary lesions suggests that CD23 expres-
sion is not related to disease outcome of MCC.
Furthermore, the expression of CD23 in neuroendo-
crine carcinomas, as well as carcinoid tumors, pro-
vides additional support to the notion that CD23 is
not related to the pathogenesis or the aggressiveness of
these tumors. An additional study with a large num-
ber of cases would help substantiate this observation.
Merkel cells are generally considered to be
derivatives of either neural crest cells or primitive
epithelium, showing both neuroendocrine and epi-
thelial features.25,26 Similarly, SMCC derived from
the amine precursor uptake and decarboxylation cells
was also thought to be of neural crest or epithelial
origin.27 The strong expression of CD23 in both
MCC and non-cutaneous SMCC suggests a possible
related histogenesis of the two.
The mechanism of the CD23 expression in MCC
and other neuroendocrine tumors is unclear. CD23 is
a type II transmembrane glycoprotein.1 The unique
punctate CD23 staining, a pattern similar to the
CK20 and/or pancytokeratin reactivity in MCC,
suggests that CD23 may cross-react with keratin/
intermediate filaments in the tumor cells. We specu-
late that the target of the cross-reaction is less likely
to be CK20. The reason is that most carcinoid tu-
mors and non-cutaneous SMCCs in our study were
strongly reactive for CD23, yet these tumors are
generally negative for CK20.8 Alternatively, CD23
may represent or be associated with an intrinsic
molecule expressed in neuroendocrine cells and tumors.
Fig. 2. The expression of cluster designation
23 (CD23) in lung small cell carcinomas
(SMCC) and carcinoid tumors. A) Hema-
toxylin and eosin sections of a lung SMCC
showing small neoplastic cells with nuclear
molding and frequent karyorrhexis (3400).
B) It shows a diffuse cytoplasmic staining
with CD23 (3400). C) A case of cutaneous
metastatic lung SMCC showing diffuse
cytoplasmic CD23 reactivity (3400). D) A
lung carcinoid tumor showing strong CD23
staining with a diffuse cytoplasmic pattern
(3400).
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Future studies are necessary to elucidate the mecha-
nism(s) of CD23 expression in neuroendocrine tumors.
Lastly, it is important to be aware that the CD23
expression is not restricted to chronic lymphocytic
leukemia/small lymphocytic lymphoma. Interest-
ingly, CD56 and the paired box-5,markers commonly
used in evaluating lymphoid malignancies, were also
found to be expressed in MCC and non-cutaneous
SMCC.14,16
In summary, we have shown that CD23 is a very
sensitive marker for MCC and other neuroendocrine
tumors. CD23 staining patterns were significantly
different between MCC and non-cutaneous SMCC.
Therefore, it could serve as an ancillarymarker in skin
tumors suspicious for neuroendocrine origin andmay
have some utility in differentiating MCC from non-
cutaneous SMCC when used in conjunction with
CK20 and TTF-1.
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